AUSTIN, Texas, March 12, 2015—XBiotech announced today that it has launched a website and call center to help patients with metastatic colorectal cancer learn about its U.S. Pivotal Phase III clinical trial. The Phase III study named, __X__ilonixTM  __C__olorectal cancer __I__mmunotherapy __T__reatment __E__valuation (“XCITE”), assesses XBiotech’s True Human™ monoclonal antibody (XilonixTM) for the treatment of metastatic colon cancer.

The website, provides the locations for all open sites, a pre-screening questionnaire to help individuals determine if they are eligible for the trial, and a call center to answer questions about the trial and site locations.

Total enrollment is expected to consist of 600 patients. The primary objective of the XCITE trial is to assess the ability of XilonixTM to improve the overall survival in patients with metastatic colorectal cancer who have failed standard therapies. XilonixTM contains an anti-inflammatory antibody, which is being tested for its ability to inhibit tumor growth and metastasis by interrupting crucial signals that are necessary for the spread of cancer. In addition, Xilonix™ may help to improve fatigue, muscle loss and anxiety caused from tumor related inflammation.


XBiotech is a leading developer of next generation therapeutic antibodies. The Company is also innovating with manufacturing technology and clinical strategies to lessen capital requirements and reduce lead times for drug development.


Ashley Otero


Recommended Articles

Image placeholder title

Ask the Experts About Circulating Tumor DNA in the Management of Cancer

Ask the Experts About Circulating Tumor DNA (ctDNA) in the Management of Cancer

Image placeholder title

Tisotumab Vedotin – Promising in Advanced Cervical Cancer

Novel precision cancer medicine promising for treatment of advanced ovarian cancer.

Image placeholder title

Checkpoint Inhibitor Immunotherapy for Treatment of Advanced Cervical Cancer

Checkpoint inhibitor immunotherapy prolongs survival and delays recurrence in advanced cervical cancer.



About OMNI Health Media:

Originally established in 1996 as a cancer patient education resource, OMNI Health Media (OMNI) has consistently expanded its platform by integrating technologic advances with its health information content, applications and clinical trial services. OMNI has been recognized for producing award-winning, multi-media content which reaches over 1.5 million health information seekers in English, Japanese, and Spanish every month. OMNI currently produces Web applications and health content in oncology, urology,  gastroenterology, rheumatology, and women’s health.

The mission of OMNI Health Media is to connect individuals with the most current, comprehensive health information and with others in similar situations. OMNI Health Media also provides services that help cancer patients find appropriate clinical trials evaluating new or novel treatment approaches. OMNI uses a variety of platforms including online, print, video, social media, and live interactive Web chats to connect and empower individuals to better manage their health conditions.

OMNI Health Media produces and manages Women magazine,,, and The Web Chats with the Experts interactive series featuring thought leaders from institutions such as Memorial Sloan Kettering, Johns Hopkins, Yale, and other prominent health centers.


Copyright © 2018 CancerConnect. All Rights Reserved.